SPYRAL AFFIRM
The SPYRAL AFFIRM Global Clinical Study of Renal Denervation With the Symplicity Spyral Renal Denervation System in Subjects With Uncontrolled Hypertension
In US patients with uncontrolled hypertension, radiofrequency renal denervation reduced office systolic blood pressure at 6 months from baseline, with no change in medication.
In a broad US population of 594 patients that included 27% African American patients and 19% with type 2 diabetes, renal denervation lowered office, home and ambulatory systolic BP at 6 months with no change in medication. The study is single-arm and has no sham control, so regression to the mean, placebo effects and changes in adherence cannot be separated from the treatment effect. The endpoint is a 6-month blood pressure surrogate, not cardiovascular events. The abstract states that adverse events were uncommon but gives no event rates, and it gives the performance goal without stating the formal comparison against it.